Sign inJoin waitlistJoin the waitlist

Mark Juckett

Professor, Division of Hematology, Oncology, and Transplantation · University of Minnesota

Credentials: · · · ·

History

University of Minnesota
Present
University of Minnesota
Present

University of Minnesota
1990–1991
Internal Medicine
University of Minnesota
1987–1990
University of Louisville School of Medicine
1983–1987

Research

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research
Biology of Blood and Marrow Transplantation · 2015 · 370 citations
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
Blood · 2021 · 295 citations
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2017 · 240 citations

Mary Horowitz
15 papers
Peiman Hematti
13 papers
Nandita Khera
11 papers
Daniel Weisdorf
10 papers
JM
Joseph Maakaron
10 papers
Mark Litzow
10 papers
Stephanie Lee
10 papers
JP
Joseph Pidala
9 papers
LB
Linda Burns
9 papers
Michael Grunwald
9 papers
Wael Saber
9 papers
Christopher Dandoy
7 papers

Grants

BMT CTN Core - University of Minnesota
National Heart, Lung, and Blood Institute · UG1
Contact PI · $882.3K · University of Minnesota
2001–2031
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $3.4K · University of Wisconsin-Madison
2005–2006
Nitric Oxide and Ferritin Mediated Tumor Cell Resistance
National Cancer Institute · K08
Contact PI · $383.1K · Medical College of Wisconsin
1996–2001
National Biomedical Esr Center
National Center for Research Resources · P41
Project lead · $32K · Medical College of Wisconsin
1997–2001

Clinical trials

Allo HSCT Using RIC and PTCy for Hematological Diseases
Principal investigator · Recruiting · Phase 2
Masonic Cancer Center, University of Minnesota
2023–2028
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Principal investigator · Terminated · Phase 1, Phase 2
GT Biopharma, Inc.
2020–2021
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
University of Wisconsin, Madison
2013–2017
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2008–2012